Novartis in Japan
This article was originally published in The Tan Sheet
Executive Summary
Consumer Health division forms joint venture with household products company Kao to introduce OTC brands in Japan. The Novartis Kao portfolio will include new products developed for the Japanese market, international brands suitable for Japan and pharmaceuticals appropriate for switching from Rx status. In January 2001, the Tokyo-based firm will launch an eyecare product for the relief of eyestrain symptoms. Other products will target fatigue, muscle aches and back pain. McNeil Consumer Healthcare recently announced a partnership with Takeda Chemical Industries to launch Tylenol analgesics in Japan (1"The Tan Sheet" July 24, p. 19)
You may also be interested in...
Novartis Kao
Joint venture created by Novartis Consumer Health, Kao Corp. to market OTCs in Japan dissolved, firms announce March 26. Partnership was created in July 2000 with a portfolio expected to include new products developed for Japanese market, international brands, Rx drugs suitable for OTC switch (1"The Tan Sheet" Aug. 7, 2000, In Brief). Parent companies realized "initial expectations were not likely to be met within the timeframe they had originally agreed upon," Novartis says, adding it remains interested in increasing its OTC presence in Japan, particularly through switches...
Novartis Kao
Joint venture created by Novartis Consumer Health, Kao Corp. to market OTCs in Japan dissolved, firms announce March 26. Partnership was created in July 2000 with a portfolio expected to include new products developed for Japanese market, international brands, Rx drugs suitable for OTC switch (1"The Tan Sheet" Aug. 7, 2000, In Brief). Parent companies realized "initial expectations were not likely to be met within the timeframe they had originally agreed upon," Novartis says, adding it remains interested in increasing its OTC presence in Japan, particularly through switches...
Novartis Kao
Joint venture created by Novartis Consumer Health, Kao Corp. to market OTCs in Japan dissolved, firms announce March 26. Partnership was created in July 2000 with a portfolio expected to include new products developed for Japanese market, international brands, Rx drugs suitable for OTC switch (1"The Tan Sheet" Aug. 7, 2000, In Brief). Parent companies realized "initial expectations were not likely to be met within the timeframe they had originally agreed upon," Novartis says, adding it remains interested in increasing its OTC presence in Japan, particularly through switches...